TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
TG Therapeutics reported positive Phase 1 results for its subcutaneous formulation of BRIUMVI, showing >60% bioavailability relative to the IV version and no new safety signals. Pharmacokinetic modeling indicates that both quarterly and every-other-month subcutaneous dosing regimens will likely meet the non-inferiority primary endpoint in the ongoing Phase 3 trial.
Key figures
- Drug Name
- BRIUMVI (ublituximab-xiiy)
- Phase Of Trial
- Phase 1
- Patients treated
- >100
- Gmr quarterly dosing
- 1.21
- Bioavailability vs iv
- >60%
- Injection site reactions
- <5%
- Gmr every other month dosing
- 1.58
- Systemic injection reactions
- ~21%
- Subcutaneous injections administered
- >225
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.